Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.43 |
| ▸ | EGFR | P00533 | 10/20 | 0.43 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | WEE1 | P30291 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14014103 | 0.90 | MAPK8 (0.49) | MAPK8FGFR1EGFRSRCFGFR2 | |
| SCHEMBL14014092 | 0.88 | MAPK14 (0.45) | MAPK8MAPK14 | |
| SCHEMBL14014108 | 0.84 | MAPK14 (0.43) | MAPK8FGFR1EGFRSRCMAPK14 | |
| SCHEMBL14014072 | 0.84 | MAPK14 (0.52) | MAPK8WEE1MAPK14 | |
| SCHEMBL14014088 | 0.82 | MAPK14 (0.56) | MAPK8MAPK14 | |
| SCHEMBL14014081 | 0.81 | MAPK14 (0.55) | MAPK8MAPK14 | |
| SCHEMBL14014195 | 0.80 | MAPK14 (0.54) | MAPK8MAPK14 | |
| SCHEMBL14014097 | 0.78 | MAPK14 (0.65) | MAPK8MAPK14 | |
| SCHEMBL14014471 | 0.78 | MAPK14 (0.53) | MAPK8MAPK14 | |
| SCHEMBL5115765 | 0.78 | MAPK8 (0.62) | MAPK8FGFR1EGFRSRCFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | MAPK8 3523/4885FGFR1 1580/4885EGFR 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.